Drug
DL-3-n-butylphthalide
DL-3-n-butylphthalide is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_4
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (50.0%)
Phase 41 (50.0%)
Trials by Status
not_yet_recruiting133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_4
Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment
NCT06508671
completedphase_1
Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
NCT02149875
completed
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
NCT02711683
Clinical Trials (3)
Showing 3 of 3 trials
NCT06508671Phase 4
Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment
NCT02149875Phase 1
Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
NCT02711683
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3